Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study
{{output}}
Patients with accelerated-phase/blast-phase myeloproliferative neoplasms (AP/BP-MPN) experience poor clinical outcomes. A multicenter, retrospective cohort study was conducted to assess outcomes of patients with AP/BP-MPN treated with hypomethylating agent (HM... ...
